Molecular profiling using NGS can help identify potential clinical trial options and should be offered especially as encouraging preliminary activity has been reported in clinical trials with IDH inhibitors in the refractory setting[55, 56], FGFR inhibitors [57, 58], panRAF inhibitors [59] and NTRK inhibitors [60] in patients with grade 2 gliomas (Level II-B). The gene discussed is IDH2; the disease is central nervous system cancer.